INTRODUCTION
In Europe, ovarian cancer is the fifth leading cause of cancer death in women (1) . Most patients with advanced disease, despite the initial treatment, have a relapse within 15 months from diagnosis and a median overall survival (OS) of 2 years after recurrence (2) .
The Response Evaluation Criteria in Solid Tumors (RECISTs) are appropriate for response assessment of cancer only when recurrent ovarian cancer (ROC) is measurable by radiologic examination (3) , but almost half of the patients with ROC have a disseminated disease that is not measurable by traditional radiologic criteria, as peritoneal carcinomatosis or ascites (4) . Consequently, other criteria for disease assessment are currently used. The elevation above the normal range of serum concentration of cancer antigen-125 (CA125), a glycoprotein expressed by 82% of ROC, is a common finding in relapsed disease. The CA125-related criteria for defining tumor response (TR) or progression have been developed by the Gynecologic Cancer Inter Group (GCIG) and are given in Table 1 (5) .
A recent series of papers by Mehrara et al. (6, 7) reported an alternative definition of response and progression, based on tumor kinetics. Parameters such as specific growth rate (SGR) and TR can be calculated from radiologic tumor diameters or from tumor serologic markers at defined time points along the course of disease and after treatments. Finally, TR allows to capture the time when the tumor cell growth returns to the pre-treatment value, and then to define when tumor regrowth comes back to its original SGR.
To date, no clinical reports are available on the feasibility of TR and SGR for determining, respectively, response and disease progression after chemotherapy (CT) in patients with ROC. The purpose of this study is to retrospectively assess the performance of CA125-related tumor kinetic variables, TR and SGR, versus GCIG criteria in predicting progression-free survivale (PFS) and OS of patients with ROC treated with CT.
PATIENTS AND METHODS
Patients were selected among women with progressive ROC, who were treated at the division of Medical Oncology of 'Giovanni Borea' Hospital in Sanremo, Italy, from January 2006 to September 2011. To be included in this study, patients must have received at least one cycle of CT, they must have had one or two increasing CA125 determinations in the 3 months before the start of CT, a CA125 determination at the time of first cycle, then at least another one at Weeks 8 and 12 thereafter, further repeated monthly determinations until disease progression. The time of death had to be reported in their clinical records. OS was measured from the first cycle of CT to death or last censoring. Finally, every patient should have signed an informed consent form for the management of her clinical record for research purposes.
The determinations of seric CA125 were performed at the 'Laboratorio Analisi' department of the 'G. Borea' Hospital. The upper value of normal range was 35 U/ml.
The GCIG response was calculated by GCIG criteria (4). CA125-TR was calculated as reported by Mehrara et al. (7) including the basal value of CA125 and determinations at Weeks 8 (TR8) and 12 (TR12). A TR of zero indicates no effect of CT, a higher TR value correlates with a more effective therapy, a negative TR expresses a post-treatment growth enhancement of ovarian cancer. Figure 1 . Tumor responses at 8 and 12 weeks (TR8 and TR12) and CA125-related growth rate (GR) in 42 patients with relapsed ovarian cancer. 1204 CA125 kinetics after CT in ROC CA125-related SGR was calculated at the time of starting CT (GR) and at the time of the next serologic progression (growth rate at progression, GRP). For GRP calculation, the first value above the double of the nadir (if nadir was .10 U/ml) or an increase of .20 U/ml (if nadir was ,10 U/ml) was considered (8) , and the formula reported by Mehrara et al. (9) was used. Patients included in this retrospective study have been selected from clinical practice; then, the time of disease progression after CT was the first occurring among serologic, clinical or radiologic progression. Then, PFS was calculated from the start of CT to the time of the first reported progression. When applicable, PFS by GCIG criteria was additionally reported, as well as PFS by GRP.
Cases were grouped into two different subgroups around the median value of TR8 and TR12, and by GCIG response, distinguishing responsive, stable and progressive disease. A regression analysis with the Kruskal-Wallis H test has been performed to test the degree of the relationship between PFS, OS and the three methods to assess TR: GCIG criteria, TR8 and TR12.
Furthermore, cases were grouped into two different subgroups around the median value of PFS by GRP and of PFS by GCIG. A regression analysis with the Mann -Whitney U test has been performed to test the degree of the relationship between the two methods to assess tumor progression, GCIG criteria and GRP, and OS.
Finally, a linear regression of GRP-PFS versus GCIG-PFS on OS and of TR versus GCIG response on PFS was performed. The analysis was performed including all the selected patients at 27 January 2012. Data were processed with the software SPSS v17.
RESULTS
From March 2006 to September 2011, 116 patients with ROC were evaluated. Among them 93 have received a cytotoxic CT, and 42 patients were elegible for the present analysis, because all CA125 measurements at the pre-specified times, necessary for the purpose of the study, were available. None of the patients at the time of the analysis had been subjected to bevacizumab or hormonal therapy. None of the patients underwent a further cytoreductive surgery. All patients had the Karnofsky performance status of 80 -100%. Patient characteristics are summarized in Table 2 . TR8, TR12 and SGR of every patient are reported in Figure 1 .
The median OS and CA125-related measures are reported in Table 3 .
The criteria for defining progressive and responsive disease used in the clinical sample are shown in Table 4 . Figure 2 reports TR8, TR12 and GR for every patient.
The correlation analyses between response criteria are reported in Table 5 , and survival curves after stratification by GCIG criteria or by TR8 are shown in Fig. 2 .
The results of the analyses concerning progression criteria have been shown in Table 6 .
DISCUSSION
The approval of new drugs and new combinations of drugs requires a test that defines the activity of the drug in terms of a response or a prolongation of time until the next progression. Of the two possible end points for Phase 2 trials, a progressionrelated end point is more sensitive to capture a possible advantage of new treatments, in particular in studies with targeted agents. Trials of ROC focused on the improvement of definition of response and progression. Even if in clinical trials response is essential for assessing drug activity, in clinical practice determining the time of progression is necessary for moving to another medical treatment. To date, GCIG criteria remain well coded, but proposals for simplification and change are often suggested. The most important limit of these criteria is the proportion of patients with normal CA125 levels. It is controversial whether to specify the time of sampling to calculate some kinetic parameters of CA125, as well as to standardize the total to three or four CA125 determinations besides the percentage of reduction. Another major limitation with the GCIG criteria is that they are not used as the sole method to determine the progression GR, CA125-related growth rate; GRP, CA125-related growth rate at progression; OS, overall survival; PFS, progression-free survival. 
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in clinical trials. Continuing to draw clinical trials with a composite endpoint of progression will reduce the possibility to compare their results each other, and will expose researchers to discordant assessment of disease progression between radiology and CA125, and will make it necessary to develop other biological or patient-reported end points. Furthermore, studies have shown a different change in the kinetics of CA125 compared with that of the tumor evaluated by Jpn J Clin Oncol 2013;43(12) 1207 radiology, depending on the type of drug used (10 -12) , and these difficulties are likely to increase with targeted therapies. Our study has many limits. Besides the low number of eligible patients, further medical treatment was initiated after serologic progression by GCIG only in 35 of 42 patients, as reported in Table 4 ; in the other patients, progression was established by clinical or radiologic criteria. It is interesting to note that the proposed criteria to define serologic progression by GRP captured progression in 37, 2 patients more (and early) than GCIG criteria. Even if in our sample GRP, similarly to GR, did not predict OS (P¼0.14), it was strongly correlated to platinum-free interval (data not published).
As expected, measures of response predicted PFS, whereas measures of progression predicted OS, and this is clearly shown in Tables 5 and 6 . A TR at 8 weeks .1.77 performed similar to a TR at 12 weeks .1.86, but differently from the GCIG criteria it defines a precise timing for response assessment in clinical trials. A more precise timing for assessing CA125-related tumor response than that of currently used GCIG criteria could allow a more simple comparison among trials. Furthermore, TR8 could allow to bypass the problem of a transitory increase of CA125 that occurs after treatment with some drugs, such as pegylated liposomal doxorubicin (PLD), and does not correlate with a radiologic progression by RECISTs or by GCIG criteria (10) . A CA125 early pseudo-progression occurred in a patient of the present study after the first cycle of CT with PLD.
TR8 could be theoretically better than CA125 half-life (CA125-HL) in predicting PFS, due to its reliability with basal values ,100 U/ml, and is simply calculated and standardizable and does not require more than three determinations at specified time points; additionally, TR8 can be applied to radiologically measurable disease. On the other hand, to date, TR8 has not been studied after CT and does not inform about the mono-or bi-exponential growth in the individual patient as half-life does (13) . However, TR8 is probably superior to CA125-HL because the pre-and post-treatment growth rates are included in its calculation.
For the purpose of this study, the timing for defining the progression for calculating GRP is based on the results of a secondary analysis of the SWOG 9701 trial (8) . In this analysis, CA125 early signal of progressive disease (CA125-EPD) predated GCIG progression with a median duration of 56 days early, with a low false-positive rate and early prediction of progression in .50% of patients (8) . For CA125-EPD, a good performance is confirmed by the present study, even if the low number of patients does not consent to define a difference from the progression calculated by the GCIG criteria. Although this trial is an indirect confirmation of reliability of CA125-EPD in predicting progression, further assessment in prospective trials of CA125-EPD versus GCIG progression is strongly recommended.
A recent paper reported an analysis of the CALYPSO trial, and it has allowed us to know the behavior of some CA125 kinetic parameters in 777 patients receiving firstline platinum-based CT (14) . Some of these parameters, although different from TR and SGR, are conceptually similar.
The study aimed at building a population kinetic-based semi-mechanistic model of CA125 kinetics, and it evaluated five kinetic parameters. Based on this model, it was possible to separate information on CA125 production, elimination and indirect treatment effect. In particular, it was interesting to note that the CA125-related tumor growth constant by semimechanistic model (BETA) did not present correlation with PFS, while the CA125 elimination rate (KELIM) did. KELIM was a kinetic parameter linked to tumor marker elimination, which can be assimilated to CA125 clearance. Though the model is different, TR8 can be assimilated to KELIM, both for the common evaluation of post-CT CA125 reduction and for the timing around 50 days. Compared with KELIM, TR8 appears to be easier to calculate and it is also theoretically applicable to tumor lesion diameters in all patients with radiologically measurable disease, even if their CA125 is in the normal range.
In conclusion, surrogate end points such as TR8 and GRP, if validated in larger studies, could consent to go ahead the present composite end points for defining response or progression, and could be intermediate end points of trials of drugs acting by cytotoxic or cytostatic mechanisms and of drug regimens including both.
